RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immuno-Biological Laboratories Co Stock

Immuno-Biological Laboratories Co Liabilities 2024

Immuno-Biological Laboratories Co Liabilities

353.27 M JPY

Ticker

4570.T

ISIN

JP3921300004

In 2024, Immuno-Biological Laboratories Co's total liabilities amounted to 353.27 M JPY, a 4.83% difference from the 336.99 M JPY total liabilities in the previous year.

Immuno-Biological Laboratories Co Aktienanalyse

What does Immuno-Biological Laboratories Co do?

Immuno-Biological Laboratories Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Immuno-Biological Laboratories Co's Liabilities

Immuno-Biological Laboratories Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Immuno-Biological Laboratories Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Immuno-Biological Laboratories Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Immuno-Biological Laboratories Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Immuno-Biological Laboratories Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Immuno-Biological Laboratories Co stock

What is the level of liabilities of Immuno-Biological Laboratories Co this year?

Immuno-Biological Laboratories Co has a debt balance of 353.27 M JPY this year.

What were the liabilities of Immuno-Biological Laboratories Co compared to the previous year?

The liabilities of Immuno-Biological Laboratories Co have increased by 4.83% increased compared to the previous year.

What are the consequences of high debt for investors of Immuno-Biological Laboratories Co?

High liabilities can pose a risk for investors of Immuno-Biological Laboratories Co, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Immuno-Biological Laboratories Co?

Low liabilities mean that Immuno-Biological Laboratories Co has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Immuno-Biological Laboratories Co affect the company?

An increase in liabilities of Immuno-Biological Laboratories Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Immuno-Biological Laboratories Co affect the company?

A decrease in the liabilities of Immuno-Biological Laboratories Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Immuno-Biological Laboratories Co?

Some factors that can influence the liabilities of Immuno-Biological Laboratories Co include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Immuno-Biological Laboratories Co so important for investors?

The liabilities of Immuno-Biological Laboratories Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Immuno-Biological Laboratories Co take to modify the liabilities?

To change its liabilities, Immuno-Biological Laboratories Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Immuno-Biological Laboratories Co pay?

Over the past 12 months, Immuno-Biological Laboratories Co paid a dividend of 5 JPY . This corresponds to a dividend yield of about 1.13 %. For the coming 12 months, Immuno-Biological Laboratories Co is expected to pay a dividend of 0 JPY.

What is the dividend yield of Immuno-Biological Laboratories Co?

The current dividend yield of Immuno-Biological Laboratories Co is 1.13 %.

When does Immuno-Biological Laboratories Co pay dividends?

Immuno-Biological Laboratories Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immuno-Biological Laboratories Co?

Immuno-Biological Laboratories Co paid dividends every year for the past 0 years.

What is the dividend of Immuno-Biological Laboratories Co?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immuno-Biological Laboratories Co located?

Immuno-Biological Laboratories Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immuno-Biological Laboratories Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immuno-Biological Laboratories Co from 6/28/2013 amounting to 50 JPY, you needed to have the stock in your portfolio before the ex-date on 3/27/2013.

When did Immuno-Biological Laboratories Co pay the last dividend?

The last dividend was paid out on 6/28/2013.

What was the dividend of Immuno-Biological Laboratories Co in the year 2023?

In the year 2023, Immuno-Biological Laboratories Co distributed 0 JPY as dividends.

In which currency does Immuno-Biological Laboratories Co pay out the dividend?

The dividends of Immuno-Biological Laboratories Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immuno-Biological Laboratories Co

Our stock analysis for Immuno-Biological Laboratories Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immuno-Biological Laboratories Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.